In 2012, Zhang et al conducted a meta-analysis to explore the role of XRCC1 Arg194Trp polymorphism in glioma risk based on 4 case-control studies [24, 27–29], and the results indicated that there was no remarkable association between them [8]. This evidence concerns the gene XRCC1 and central nervous system cancer.